Company
PetMed Express, Inc.
Headquarters: Delray Beach, FL, United States
Founded: 1996
Employees: 219
CEO: Mr. Matthew N. Hulett
Market Cap
$79.7 Million
USD as of July 1, 2024
PetMed Express, Inc. Categories
United States Healthcare Pharmaceutical RetailersUnited States Healthcare United States Pharmaceutical Retailers
Top Competitors by Market Capitalization
Industry: Pharmaceutical Retailers
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Detailed Description
PetMed Express, Inc., together with its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, and other health products for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, strollers, and other pet supplies. It sells its products through its Internet website and mobile app; telephone contact center; and direct mail/print through catalogs, brochures, and postcards. PetMed Express, Inc. was incorporated in 1996 and is headquartered in Delray Beach, Florida.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
PetMed Express, Inc. has the following listings and related stock indices.
Stock: NASDAQ: PETS wb_incandescent
Stock: FSX: PQM wb_incandescent
Product & Services
Animal drugs
Key People
Founder(s): Marc Puleo
Matthew N. Hulett (CEO)
Financials
Revenue: US$284.1 million (2020)US$283.4 million (2019)